| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0272-2712(03)00025-8 |
| P698 | PubMed publication ID | 12848451 |
| P2093 | author name string | Jacob A Canick | |
| Geralyn M Lambert-Messerlian | |||
| Devereux N Saller | |||
| P2860 | cites work | Effect of study design on the association between nuchal translucency measurement and Down syndrome | Q33765142 |
| First trimester screening for aneuploidy: serum biochemical markers | Q33768998 | ||
| First trimester screening for aneuploidy: nuchal translucency sonography | Q33769004 | ||
| Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement | Q34356065 | ||
| Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. | Q34375938 | ||
| Maternal serum screening for Down's syndrome in early pregnancy | Q35703368 | ||
| Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy | Q35822995 | ||
| Antenatal screening for Down's syndrome. | Q40909255 | ||
| Chorionic villus sampling and amniocentesis for prenatal diagnosis | Q41392204 | ||
| Multiple-marker screening in pregnancies with hydropic and nonhydropic Turner syndrome | Q41924002 | ||
| Defective cholesterol biosynthesis associated with the Smith-Lemli-Opitz syndrome | Q41929357 | ||
| Assigning risk for Smith-Lemli-Opitz syndrome as part of 2nd trimester screening for Down's syndrome | Q43954476 | ||
| Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities | Q44259917 | ||
| Chromosomal abnormality rates at amniocentesis and in live-born infants | Q46381824 | ||
| Participation in maternal serum screening following screen positive results in a previous pregnancy. | Q51080906 | ||
| Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. | Q52133970 | ||
| Risk-based prenatal screening for trisomy 18 using alpha-fetoprotein, unconjugated oestriol and human chorionic gonadotropin. | Q52335333 | ||
| Assay precision of serum alpha fetoprotein in antenatal screening for neural tube defects and Down's syndrome. | Q53904391 | ||
| Maternal serum screening for Down syndrome in the United States: a 1995 survey. | Q53970056 | ||
| Nuchal fluid accumulation in trisomy-21 detected by vaginosonography in first trimester. | Q55052253 | ||
| Absence of nasal bone in fetuses with trisomy 21 at 11–14 weeks of gestation: an observational study | Q56764725 | ||
| Free beta-hCG as first-trimester marker for fetal trisomy | Q67537231 | ||
| Maternal serum Down syndrome screening: Free β-protein is a more effective marker than human chorionic gonadotropin | Q67673897 | ||
| Prenatal screening for trisomy 18 in the second trimester | Q67678252 | ||
| Maternal serum hCG levels in triploidy: variability and need to consider molar tissue | Q68023385 | ||
| Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome | Q69029876 | ||
| Combining maternal serum alpha-fetoprotein measurements and age to screen for Down syndrome in pregnant women under age 35. New England Regional Genetics Group Prenatal Collaborative Study of Down Syndrome Screening | Q69059112 | ||
| Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome | Q70056433 | ||
| Prenatal diagnosis of Down's syndrome | Q70089435 | ||
| Serum alpha-fetoprotein and neural tube defects in the first trimester of pregnancy. MRC Vitamin Study Research Group | Q71615457 | ||
| Four-marker serum screening for Down's syndrome | Q71661694 | ||
| Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice | Q71753811 | ||
| Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype | Q72080653 | ||
| An association between low maternal serum α-fetoprotein and fetal chromosomal abnormalities | Q72729435 | ||
| Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome | Q72730932 | ||
| Second-trimester maternal serum analyte levels associated with fetal trisomy 13 | Q73084033 | ||
| Screening for triploidy by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation | Q73911772 | ||
| Screening of maternal serum for fetal Down's syndrome in the first trimester | Q74378735 | ||
| Levels of unconjugated estriol and other maternal serum markers in pregnancies with Smith-Lemli-Opitz (RSH) syndrome fetuses | Q74529027 | ||
| Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops | Q77594394 | ||
| Natural history of Down's syndrome: a brief review for those involved in antenatal screening | Q77957746 | ||
| Integrated screening for Down's syndrome based on tests performed during the first and second trimesters | Q78109767 | ||
| A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A | Q78368763 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Down syndrome | Q47715 |
| P304 | page(s) | 395-411 | |
| P577 | publication date | 2003-06-01 | |
| P1433 | published in | Clinics in laboratory medicine | Q26841969 |
| P1476 | title | Prenatal screening for Down syndrome: current and future methods | |
| P478 | volume | 23 |
Search more.